Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline Programs

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, expecting gross proceeds of approximately $100 million. The offering includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions. The transaction is anticipated to close on or about July 1, 2026, subject to customary closing conditions.

The company plans to use the net proceeds primarily to advance development of its key programs: NXP100, NXP200, and NXP900. Additionally, funds will support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. Cantor is acting as the sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners serving as co-managers.

Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a complement Factor B inhibitor for complement-mediated diseases; NXP900, an oral SRC family kinase inhibitor targeting solid tumors; and NXP200, a brain-penetrant BRAF inhibitor for various cancers. The successful completion of this offering provides the company with significant capital to accelerate these programs through clinical development.

For more details, the full press release is available at https://ibn.fm/SrZnr.